DGX
QUEST DIAGNOSTICS INCEvidence as of 2026-09-02Overview · QUEST DIAGNOSTICS INC
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand,…
Management team
- Mr. Gary D. Samuels · Senior VP & Chief Communications OfficerFind on LinkedIn
- Ms. Kristin Lee Wallace Esq. · Senior VP & Chief Compliance OfficerFind on LinkedIn
- Mr. Shawn C. Bevec · Vice President of Investor RelationsFind on LinkedIn
- Ms. Gabrielle Wolfson · Senior VP and Chief Information & Digital OfficerFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.1 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The evidence balance is Mixed (+ 0.1 of a possible + 2; confidence high). For the fiscal quarter ended 2026-07-15 (Q2 2026), reported revenue was $ 3,043,000,000 and Cost of Revenue was $ 2,016,000,000, implying gross profit of $ 1,027,000,000; year‑over‑year revenue rose from $ 2,761,000,000 in Q2 2025 to $ 3,043,000,000 and gross profit rose from $ 943,000,000 to $ 1,027,000,000. Net income for the comparable quarter increased from $ 282,000,000 to $ 320,000,000 and diluted EPS from $ 2.47 to $ 2.84, while weighted‑average diluted shares outstanding edged down to 112,000,000 and reported shares outstanding were 110,373,360 as of 15 July 2026.
Market and capital‑structure evidence survived the review: price sat above the 50‑day SMA by + 4.9% and above the 200‑day SMA by + 18.6% with a golden_cross flag true, short‑term realized volatility was elevated (30‑day annualized + 28.4%), trailing twelve‑month P/E was 24.33, EV/EBITDA was 13.76, trailing twelve‑month FCF was $ 378,000,000 with price/FCF at 69.99, market cap was $ 26,072,395,099 and enterprise value $ 31,088,395,099, and long‑term debt had fallen from $ 6,217,000,000 as of 31 December 2024 to $ 5,642,000,000 as of 30 June 2026. Insider filings in the supplied packet show aggregate insider sales of $ 5.5M and no reported insider buys in the 180‑day window; reported institutional 13F holdings in the supplied snapshot were small and stale ( $ 3.3M as of 2025-09-30).
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenue for the fiscal quarter ended 30 June 2026 (fiscal Q2 2026, 2026-04-01 to 2026-06-30) was $3,043,000,000 while Cost of Revenue for the same quarter was $2,016,000,000, implying gross profit of $1,027,000,000 for that quarter.
XBRL companyfacts · 0001022079-26-000070Comparing like quarters, revenue rose from $2,761,000,000 in fiscal Q2 2025 (2025-04-01 to 2025-06-30) to $3,043,000,000 in fiscal Q2 2026 (2026-04-01 to 2026-06-30); Cost of Revenue rose from $1,818,000,000 in fiscal Q2 2025 to $2,016,000,000 in fiscal Q2 2026, and gross profit increased from $943,000,000 to $1,027,000,000 over that year-over-year quarter comparison.
XBRL companyfacts · 0001022079-25-000175Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
A Form 4 was filed on 2026-08-31 (the 4 filed 31 August 2026).
4 filed 2026-08-31The filing record's parse_status is listed as "pending" in the provided evidence for the Form 4 filed on 2026-08-31.
4 filed 2026-08-31Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Three-month momentum was +22.8% as of 2026-09-01.
Moneyta signal set · 2026-09-01weakened in debateTwelve-month momentum (12_1) was +41.0% and its cross-sectional rank was the 79th percentile of 547 as of 2026-09-01.
Moneyta signal set · 2026-09-01weakened in debateReads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
Reported 13F institutional holdings total $3.3M as of 2025-09-30.
13F holdings · 1 filers · as of 2025-09-30The reported institutional value declined 35.6% quarter-over-quarter and the reported holder count fell by 1 as of the 13F period ended 2025-09-30.
13F holdings · 1 filers · as of 2025-09-30Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
Multiple outlets report a multi‑year partnership with Renalytix to expand kidneyintelX.dkd testing nationwide through Quest Diagnostics' network (coverage highlights access to specialty kidney diagnostics).
News · simplywall.st · 2026-09-01At least one outlet separately covered the Renalytix–Quest Diagnostics partnership as a standalone story about expanding access to kidneyintelX.dkd testing nationwide.
News · kalkinemedia.com · 2026-09-01Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Across the reported Form 4 filings dated 28 August 2026, the insider activity shows total insider sales of "$5.5M" and total insider buys of "$0" in the 180-day window, with net shares of "-22677".
Form 4 · PREVOZNIK MICHAEL E (SVP & General Counsel) · $2.5M code M · 2026-08-28On 28 August 2026, PREVOZNIK MICHAEL E (SVP & General Counsel) reported a transaction labeled "code M" for "22677" shares with value "$2.5M" (same filing shows the trade as occurring under a trading plan).
Form 4 · PREVOZNIK MICHAEL E (SVP & General Counsel) · $2.5M code M · 2026-08-28Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model-implied free cash flow (FCF) growth rate that today's price would justify is 0.4281 (42.81%).
Valuation inputs · SEC XBRL + stored EOD closePrice-to-free-cash-flow (price/FCF) based on trailing twelve months FCF is 69.99.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
The provided evidence shows sequential and year-over-year operational improvement: Q2 2026 revenue, gross profit, net income, and diluted EPS all rose versus Q2 2025 (fundamentals-0, fundamentals-1, fundamentals-2). Share counts have trended modestly lower while long-term debt declined versus the 2024 year-end, improving per-share metrics and capital structure comparatives (fundamentals-3, fundamentals-4). Market signals show strong recent momentum, price above key moving averages with a golden cross, low beta/correlation to SPY, and solid relative strength versus the index (market-0, market-1, market-2, market-5), while ETF inclusions and news of a multi‑year Renalytix partnership expand distribution and potential addressable-market reach through Quest’s network (ownership-2, news-0, news-1). These operational and market-read signals jointly support a favorable read on the firm’s recent performance and market positioning.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.37
37 surviving claims rest on 15 distinct sources; the heaviest analyst carries 22% of them, and 97% of what the desk raised survived the debate.
The evidence base is moderately diversified across 15 distinct sources, which supports the surviving claims but leaves some dependence on a few key contributors — the single heaviest analyst supplying 22% of claims means individual bias could sway interpretation. The desk’s high survival rate from debate (97%) indicates the claims were broadly defensible in review, but survival alone doesn’t guarantee completeness; source concentration and analyst weight make these reads somewhat fragile to new contradictory filings or market moves.
Peer context · computed, not argued
12-1 momentum ranks 1st of 4 in Diagnostics & Research (as of 2026-09-01).
6-month relative strength ranks 2nd of 4 in Diagnostics & Research (as of 2026-09-01).
90-day volatility ranks 4th of 4 in Diagnostics & Research (as of 2026-09-01).
dividend yield ranks 1st of 4 in Diagnostics & Research (as of 2026-09-01).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
16 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+1.0 to the score
1 document
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash+0.4 to the score
3 holdings records· 1 cited
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis−0.3 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 filing
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state — stated and inferred flags kept apart.
Read by Talbot−0.8 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on DGX Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.